Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.

Recruiting now

Conditions studied: Coronary Artery Disease

In brief

Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.

Key facts

Study ID

NCT07068490

Run by

Samsung Medical Center

People needed

100000

Starts

2024-10-22

Expected to finish

2025-12-31

Last updated by the study team

2025-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who underwent PCI
• Use of either clopidogrel, prasugrel, or ticagrelor in combination with aspirin
• No use of PCAB, PPI, or an H2-receptor within the past month

You may not qualify if…

• Patients with low GI bleeding risk are taken on PPI
• Patients with high GI bleeding risk do not take PPI

Where it is running

• Samsung Medical Center — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.